Kaitlin Carroll, MPH, PhD

Kaitlin Carroll, MPH, PhD

Chief Operations OfficerOfficers & Management Team

Kaitlin M. Carroll, MPH, PhD, is a senior clinical and regulatory leader with 15+ years spanning academic medicine and industry, with training and early research experience at Massachusetts General Hospital and deep roots in Hospital for Special Surgery (HSS) / Weill Cornell–affiliated orthopedics and device innovation programs. She has led high-stakes regulatory pathways, including three FDA De Novo classifications and multiple FDA 510(k) clearances, and has executed clinical programs across medical affairs, clinical operations, and pharmacovigilance. Her track record includes building and running clinical teams, activating multi-site trials and agreements, and delivering the evidence packages that move new technologies from development to real-world adoption. Her work has also contributed to peer-reviewed research and national discussions on outcomes, safety, and policy in orthopedic care.

Back to Leadership

Disclaimer: The information provided on this website is intended for general educational and informational purposes only. Vesalius Longevity Labs provides information relating to peptide science, longevity, wellness, metabolic health, and emerging areas of medical research.

FDA Approval & Investigational Therapies: Not all peptides, compounds, medications, or therapies discussed or referenced on this website are approved by the U.S. Food and Drug Administration (FDA). Certain compounds may be investigational, have limited clinical evidence, or lack established long-term safety and efficacy data. References to scientific research, emerging therapies, or potential health benefits are provided for informational purposes and should not be interpreted as claims of FDA approval, established clinical effectiveness, or guaranteed therapeutic outcomes. Where legally permitted, certain medications may be compounded by appropriately licensed pharmacies in accordance with applicable federal and state laws. Compounded medications are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before marketing in the same manner as FDA-approved medications. Read the full disclaimer.